Streptococcus pneumoniae is a causative agent of pneumonia, meningitis, and otitis media.Every year, diseases caused by pneumococcal bacteria threaten the lives of billions of people worldwide:
- With nearly 1 million deaths annually in children under 5 years of age, pneumonia remains a major global health threat.
- 83% of children under 3 years of age contract meningitis. 50% of these cases result in death, and 30–50% suffer from long-term sequelae such as deafness, blindness, paralysis, epilepsy, and intellectual disability.
- There are over 350 million cases of acute otitis media in children under 5 years of age, with more than one-third experiencing recurrent infections requiring surgical intervention.
In addition to the Synflorix pneumococcal vaccine for children under 5, adults, the elderly, and individuals with chronic conditions now have access to the Prevenar 13 vaccine. This vaccine prevents invasive pneumococcal diseases that pose risks to both children and adults, such as pneumonia, meningitis, acute otitis media, and septicemia (blood poisoning).
Information regarding the Prevenar 13 vaccine (Belgium)
- The Prevenar 13 pneumococcal vaccine is a 13-valent pneumococcal conjugate vaccine. It plays a crucial role in inducing active immunity to prevent invasive disease, otitis media, and acute pneumonia caused by Streptococcus pneumoniae across various age groups.
Origin:
- The Prevenar 13 vaccine was researched and developed by Pfizer (USA), a world-leading pharmaceutical and biopharmaceutical corporation. It is manufactured in Belgium.
Indications:
- The Prevenar 13 vaccine prevents invasive pneumococcal diseases that are dangerous to children and adults, such as pneumonia, meningitis, acute otitis media, and septicemia (blood poisoning) caused by the bacterium Streptococcus pneumoniae.
Target population:
- Children, starting from 6 weeks of age.
- Adults.
- The elderly and individuals with chronic conditions such as chronic obstructive pulmonary disease (COPD), pulmonary tuberculosis, cardiovascular disease, and diabetes.
Vaccination Schedule:
Children from 6 weeks to 6 months of age: 3-dose primary series
- Dose 1: Initial vaccination.
- Dose 2: At least 1 month after Dose 1.
- Dose 3: At least 1 month after Dose 2.
- Booster dose: Administered between 11 and 15 months of age, at least 2 months after Dose 3.
- Note: The first dose of the vaccination regimen can be initiated at 6 weeks of age.
Children from 7 to 11 months of age (previously unvaccinated): 2-dose primary series
- Dose 1: Initial vaccination.
- Dose 2: At least 1 month after Dose 1.
- Booster dose: Administered after 1 year of age.
- Note: The booster dose must be administered at least 2 months after Dose 2.
Children from 12 to 23 months of age (previously unvaccinated):
- Dose 1: Initial vaccination.
- Dose 2: At least 2 months after Dose 1.
Children from 24 months of age to adults: Single dose
The Prevenar pneumococcal vaccine, manufactured by Pfizer (UK), is currently distributed in over 100 countries worldwide. Its safety and efficacy in both adults and children have been clinically proven.
PLEASE VISIT YOUR NEAREST VACCINATION CENTER FOR CONSULTATION AND VACCINATION TODAYContact Information:
HANOI MEDICAL UNIVERSITY VACCINATION CENTER "Safe - Attentive - Reliable"
Facility 1: No. 1 Ton That Tung, Dong Da District, Hanoi.Facility 2: No. 35 Le Van Thiem, Thanh Xuan District, Hanoi.
Operating Hours: - Monday to Sunday morning
- Morning: 08:00 – 11:30 - Afternoon: 13:30 – 16:30
Fanpage: https://www.facebook.com/phongtiemchungdhy
https://www.facebook.com/phongtiemchungdhycoso2
Hotline: 02462597231 / 0868098399